Clinical Trial

An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Enrolling by Invitation Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of extended dosing with eplontersen in participants with ATTR-CM.
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2022-12-19; most recent amendment 2026-04-16.
Status change: Recruiting → Enrolling by Invitation 2025-06-29
Trial Details
NCT Number NCT05667493
Lead Sponsor Ionis Pharmaceuticals, Inc.
Collaborators: AstraZeneca
Conditions Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM)
Enrollment 1,400 participants
Start Date 2022-11-30
Primary Completion 2029-08 (estimated)
Study Completion 2029-08 (estimated)
Updated on ClinicalTrials.gov 2026-04-17